Debt Finance

By tapping into innovative new products and structures, the debt finance market is making the most of the current high-cost environment. In this special report, we examine the impact that NAV financing has had on the sector; how pharma royalties are being used as a highly specialised debt tool; and how the industry can future-proof itself against macroeconomic change.

LATEST NEWS & ANALYSIS

Side Letter: Scarcity value

Fresh insights Scarcity value It's a heck of a time to own a secondaries firm. The strategy's...

Blue Owl’s Lipschultz seeks to quell fears of ‘red flags’ in software portfolio

Executives on the firm's latest earnings call said only 8% of AUM is in software lending, with strong loan-to-value ratios.

Stressed out: How private equity is weathering higher-for-longer

Deferred interest payments and a series of high-profile leveraged loan defaults in the US point to signs of stress within private equity portfolios. Should LPs be concerned?

Side Letter: Warnings from a UK PE doyenne

In today's edition, A veteran of UK private capital markets says the rise of private credit could lead to GFC-like concerns; Fundraising round-ups across infra, VC, impact, private debt and secondaries; Evergreens' love affair with secondaries looks set to continue.

AIG uses fund stake transfer to seed CVC $1.5bn evergreen portfolio

The pair will eye 'additional areas of collaboration' amid the insurer's plans to raise its alternatives exposure.

Click here to access Private Equity International’s in-depth special reports covering a wide array of topics, plus our digital magazines.

Subscribe now to gain unlimited access to our latest insights, analysis and reports

SEE SUBSCRIPTION OPTIONS
pei
pei

Copyright PEI Media

Not for publication, email or dissemination